Thomas Scammell, MD

home / authors / thomas-scammell-md

Articles

Unmet Needs in Narcolepsy and Clinical Pearls

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 24th 2023

Neurology experts discuss the unmet needs in narcolepsy treatment and share clinical pearls from their experiences.

Sodium Oxybate and Antidepressants for Treatment of Cataplexy

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 24th 2023

Experts discuss sodium oxybate and antidepressants for treatment of cataplexy.

Solriamfetol Efficacy and Safety

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 24th 2023

Experts discuss the efficacy and safety profile of solriamfetol for the treatment of narcolepsy.

Pitolisant Efficacy and Safety

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 17th 2023

Anne Marie Morse, DO, FAASM, discusses the efficacy and safety profile of pitolisant for the treatment of narcolepsy.

Pitolisant: Mechanism of Action

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 17th 2023

Thomas E. Scammell, MD, provides an overview of the mechanism of action of pitolisant for the treatment of narcolepsy.

EDS and Narcolepsy Treatment Options

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 10th 2023

Neurology experts discuss excessive daytime sleepiness (EDS) and narcolepsy treatment options.

Pharmacological Treatment Options for Narcolepsy

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 10th 2023

Karl Doghramji, MD, FAASM, DFAPA, provides an overview of the pharmacological treatment options for narcolepsy.

Goals of Therapy for Narcolepsy

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

May 3rd 2023

Neurology experts describe the goals of therapy for narcolepsy treatment.

Available Resources for Narcolepsy Treatment

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Debra Stultz, MD ;Anne Marie Morse, DO, FAASM

May 3rd 2023

Debra Stultz, MD, provides an overview of the available resources that are available for narcolepsy treatment.

EDS Evaluation

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

April 26th 2023

Thomas E. Scammell, MD, discusses evaluating excessive daytime sleepiness (EDS).

Diagnosis of Narcolepsy

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

April 26th 2023

Experts discuss narcolepsy diagnosis and the challenges associated with it.

Burden and Risk Factor of Narcolepsy

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

April 19th 2023

Anne Marie Morse, DO, FAASM, discusses the burden and risk factors associated with excessive daytime sleepiness and narcolepsy.

Narcolepsy Overview

Michael J. Thorpy, MD;Thomas Scammell, MD;Karl Doghramji, MD;Anne Marie Morse, DO, FAASM ;Debra Stultz, MD

April 19th 2023

Experts provide an overview of excessive daytime sleepiness and narcolepsy.

The Potential of MCHR1 Antagonists in Narcolepsy: Thomas Scammell, MD

Thomas Scammell, MD

November 2nd 2021

The professor of neurology at Beth Israel Deaconess Medical Center discussed the treatment potential of melanin concentrating hormone receptor 1 antagonists for narcolepsy. [WATCH TIME: 3 minutes]

Latest Updated Articles

Published: March 27th 2025 | Updated: March 28th 2025

FDA Approves Diazoxide Choline Extended-Release Tablets for Hyperphagia in Prader-Willi Syndrome

Published: March 4th 2025 | Updated: March 19th 2025

BTK Inhibitor Tolebrutinib Shows Greater Effectiveness in Multiple Sclerosis with Higher Paramagnetic Rim Lesion Counts

Published: January 30th 2025 | Updated: February 21st 2025

FDA Approves Vertex Pharmaceuticals' Suzetrigine for Acute Pain Management

Published: February 15th 2025 | Updated: February 18th 2025

Cerebrospinal Fluid Lipids Shows Promise as Biomarkers for Differentiating NMOSD and MS

Published: February 4th 2025 | Updated: February 6th 2025

FDA Approves Apomorphine Infusion Device SPN-830 as New Parkinson Treatment

Published: January 30th 2025 | Updated: February 4th 2025

FDA Approves Axsome Therapeutics’ AXS-07 for Migraine Treatment